



SKC's PLANNED 2020 RESEARCH PROGRAMS

Improving survival outcomes for children with high-risk cancers requires a multi-front action.

SKC has a strategic approach in funding research towards our goal. We help bring more curative and less toxic treatments to children through clinical trial research and drive trials at each phase of their treatment journey to help children who are newly diagnosed, resistant to standard treatment and at relapse. SKC identifies, prioritizes and fast-tracks trials that incorporate the latest scientific breakthroughs. For 2020, we urgently require funding for our planned projects highlighted below:

- The very first clinical trial specifically for children who have treatment-resistant neuroblastoma (a poor-prognosis solid tumor) including discovery of the mechanisms which cause resistance. Our research advocacy will ensure this trial is a transatlantic collaboration of centers.
- Creating a new ultra-high-risk subgroup of neuroblastoma by establishing a consensus of biomarkers so that these patients can have specific clinical trials to improve their dismal survival prognosis. We established an international task force to undertake the research work to accomplish this breakthrough program.
- A new trial for children with sarcoma that will use novel treatment strategies for newly diagnosed children – much earlier than standard trials which introduce these treatments after all else fails
- An international clinical trial that utilizes a triplet combination of immunotherapy and targeted radiotherapy that builds on the efficacy success of single agent immunotherapy for children with relapsed neuroblastoma
- A new trial that investigates using immune Natural Killer Cells donated from parents and engineered to massively expand, combined with a therapeutic humanized antibody for children with osteosarcoma and neuroblastoma

SKC utilizes a collaborative funding model with other charity partners to leverage our funds, scale and impact. The funds we are able to raise in May allows us to secure these collaborative funding partnerships so that we can launch these trials ASAP.